Company News Archives

Company News Press Release

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Paris, France 18 January, 2024 – Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the approval of its trientine tetrahydrochloride product by China’s…

adminJanuary 18, 2024

Company News

Tackling rare diseases: Wilson disease patient and millions more like her need help

Over the years, I’ve been deeply moved by the stories of many patients, but one particularly stands out. A woman talked about her teenage daughter’s Wilson disease — a rare…

Minesh KothariSeptember 25, 2023

Company News

Why We Should Care About Rare Disease Research – Life Science Leader

Why We Should Care About Rare Disease Research “Access to life-saving or life-enhancing treatments should not be determined by the rarity of the disease; on the contrary, our greater understanding…

adminMay 9, 2023

Company News

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

DNA Today is a multi-award-winning podcast and radio show exploring how genetics impacts our health. Host/Producer Kira Dineen interviews leaders in genetics including genetic counsellors, researchers, physicians, and patient advocates…

Minesh KothariFebruary 6, 2023

Company News Video

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™ in this video: https://www.youtube.com/watch?v=Yu2WsUwtayE

adminMay 3, 2022

Company News

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Friday 25 June Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine. This is the first trial of its…

adminJune 25, 2021

Disclaimer: This website is intended for global audience. The information available on this Website is for information purposes only.

We work in a highly regulated industry with unique legal considerations. Medical and health information may be presented but the content we share is not intended to provide professional medical advice, diagnosis or treatment.

Always seek medical advice from a qualified health care professional for any questions you may have regarding your medical condition.

To report an adverse event experience for any Orphalan product please contact us by writing to AdverseEventReporting@orphalan.com or call direct: +356 2776 1718, or call the local toll free telephone number listed under your country and choosing option 3.

Company News

Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease

Tackling rare diseases: Wilson disease patient and millions more like her need help

Why We Should Care About Rare Disease Research – Life Science Leader

Podcast: Naseem Amin, Orphalan CEO, discusses Wilson’s Disease and the potential advancements in its treatments on DNA Today

Dr. Naseem Amin, Chief Executive Officer at Orphalan, discusses the announcement of the FDA approval of Cuvrior™

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Global Headquarters

Legal

Useful Links